Clinical utility of insulin and insulin analogs

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Islets

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4161/isl.24590PMID 23584214PMCID PMC4204021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013.

  2015cited by this paper
• The need for better insulin therapy

  2013cited by this paper
• Insulin Degludec — A New Ultralong-Acting Insulin

  2013cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily

  2013cited by this paper
• Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011.

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Insulin degludec in Type 1 diabetes

  2013cited by this paper
• Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes

  2012cited by this paper
• Therapeutic potential of VIP vs PACAP in diabetes.

  2012cited by this paper
• pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications.

  2012cited by this paper
• By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012.

  2012cited by this paper
• Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

  2012cited by this paper
• Leptin for type 1 diabetes: coming onto stage to be (or not?)

  2012cited by this paper
• Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2

  2012cited by this paper
• Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

  2012cited by this paper
• Insulin and its analogues and their affinities for the IGF1 receptor.

  2012cited by this paper
• Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec

  2012cited by this paper
• Can a Tool That Automates Insulin Titration Be a Key to Diabetes Management?

  2012cited by this paper
• Insulin degludec: a new ultra-longacting insulin.

  2012cited by this paper
• Correlation of worldwide incidence of type 1 diabetes (DiaMond) with prevalence of asthma and atopic eczema (ISAAC)

  2012cited by this paper
• Global prevalence and future of diabetes mellitus.

  2012cited by this paper
• Current updates in the medical management of obesity.

  2012cited by this paper
• Insulin gene therapy from design to beta cell generation

  2012cited by this paper
• The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries

  2012cited by this paper
• Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results.

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes

  2011cited by this paper
• Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review.

  2011cited by this paper
• Strict glycemic control and mortality risk among US adults with type 2 diabetes.

  2011cited by this paper
• Insulin Degludec in Type 1 Diabetes

  2011cited by this paper
• Diabetes Care for Emerging Adults: Recommendations for Transition From Pediatric to Adult Diabetes Care Systems

  2011cited by this paper
• Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon

  2011cited by this paper
• Insulin Preparations with Prolonged Effect

  2011cited by this paper
• Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

  2011cited by this paper
• Tracing of islet graft survival by way of in vivo fluorescence imaging

  2011cited by this paper
• New Technologies in Pediatric Diabetes Care

  2011cited by this paper
• Addressing barriers to initiation of insulin in patients with type 2 diabetes.

  2010cited by this paper
• The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

  2010cited by this paper
• Insulin Patch Pumps: Their Development and Future in Closed-Loop Systems

  2010cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes

  2009cited by this paper
• Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

  2009cited by this paper
• The beneficial effects of C-Peptide on diabetic polyneuropathy.

  2009cited by this paper
• Proinsulin and the Genetics of Diabetes Mellitus*

  2009cited by this paper
• Insulin Analog Therapy: Improving the Match With Physiologic Insulin Secretion

  2009cited by this paper
• Insulin Therapy and Type 2 Diabetes: Management of Weight Gain

  2009cited by this paper
• Insulin Glulisine

  2009cited by this paper
• Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

  2009cited by this paper
• Oral Insulin and Buccal Insulin: A Critical Reappraisal

  2009cited by this paper
• High Levels of Endogenous Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression Correlate With Increased Cell Death in Human Pancreas

  2008cited by this paper
• Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008 The recommendations in this article are based on the evidence reviewed in the following publication: Standards of care for diabetes (Technical Review). Diabetes Care 17:1514–1522, 1994. Originally approved 1988. Most recent review/revision, October 2007.

  2008cited by this paper
• Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

  2008cited by this paper
• Molecular mechanisms of death ligand‐mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes

  2008cited by this paper
• Inhaled insulin--does it become reality?

  2008cited by this paper
• An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment.

  2008cited by this paper
• Weight changes following the initiation of new anti‐hyperglycaemic therapies

  2007cited by this paper
• Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter

  2007cited by this paper
• Type 2 Diabetes: Hypoinsulinism, Hyperinsulinism, or Both?

  2007cited by this paper
• Inhaled insulin for controlling blood glucose in patients with diabetes

  2007cited by this paper
• Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

  2007cited by this paper
• Immunological responses to exogenous insulin.

  2007cited by this paper
• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes

  2006cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2006cited by this paper
• Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspart

  2006cited by this paper
• Insulin analogues [5] (multiple letters)

  2005cited by this paper
• Insulin analogues.

  2005cited by this paper
• ‘Glucose control-related’ and ‘non-glucose control-related’ effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients

  2005cited by this paper
• Insulin analogues.

  2005cited by this paper
• Strategic opportunities in clinical islet transplantation.

  2005cited by this paper
• Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus.

  2005cited by this paper
• Study of the insulin dimerization: Binding free energy calculations and per‐residue free energy decomposition

  2005cited by this paper
• Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.

  2005cited by this paper
• Pharmacological Agents That Directly Modulate Insulin Secretion

  2003cited by this paper
• Role of the Connecting Peptide in Insulin Biosynthesis*

  2003cited by this paper
• Modeling phasic insulin release: immediate and time-dependent effects of glucose.

  2002cited by this paper
• Self-Association Properties of Monomeric Insulin Analogs Under Formulation Conditions

  1998cited by this paper
• Meal Composition is a Determinant of Lispro-Induced Hypoglycemia in IDDM

  1997cited by this paper
• Insulin Lispro in CSII: Results of a Double-Blind Crossover Study

  1997cited by this paper
• Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus.

  1997cited by this paper
• Insulin Lispro: Its Role in the Treatment of Diabetes Mellitus

  1996cited by this paper
• The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals.

  1996cited by this paper
• Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function.

  1995cited by this paper
• Diabetes control and complications.

  1995cited by this paper
• [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin

  1994cited by this paper
• Dietary Fat Predicts Conversion From Impaired Glucose Tolerance to NIDDM: The San Luis Valley Diabetes Study

  1994cited by this paper
• The role of technology in diabetes therapy.

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• New Directions in Drug Development: Mixtures, Analogues, and Modeling

  1993cited by this paper
• Lower-Extremity Amputations in Diabetic and Nondiabetic Patients: A population-based study in eastern Finland

  1993cited by this paper
• Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B cells predominantly via a regulated, rather than a constitutive, pathway

  1987cited by this paper
• Insulin allergy

  1986cited by this paper

• Role of Ultra-Rapid Acting Insulin in Managing Diabetes

  2026cites this paper
• Anti-diabetic Biologicals: Exploring the Role of Different Analytical Techniques.

  2025cites this paper
• Assessment of insulin pen injection practices and the effectiveness of pharmacist interventions in improving injection technique among patients with diabetes mellitus

  2025cites this paper
• Innovative approaches in insulin delivery: Exploring molecular techniques and system developments

  2025cites this paper
• The ‘Designer’ Artificial Pancreas: How Does Current Technology Mimic Pancreatic Physiology?

  2025cites this paper
• New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survival via suppression of TXNIP/NLRP3 pyroptosis signaling in Streptozocin–Induced diabetes mellitestype-1 in rats

  2024cites this paper
• Antidiabetic Herbs and Polyherbal Strategies: A Dual Approach to Diabetes Control

  2024cites this paper
• An Overview on Equipment and Preparation for Insulin

  2024cites this paper
• Prandial Insulins: A Person-Centered Choice

  2024cites this paper
• Insulin's Legacy: A Century of Breakthroughs and Innovation.

  2024cites this paper
• Insulin-induced lipodystrophy and predisposing factors in children and adolescents with type 1 diabetes mellitus (T1DM) in a tertiary care Egyptian center

  2023cites this paper
• An observational multi-center study on type 2 diabetes treatment prescribing pattern and patient adherence to treatment

  2023cites this paper
• Acute nicotine intake increases feeding behavior through decreasing glucagon signaling in dependent male and female rats.

  2023cites this paper
• Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus

  2023cites this paper
• Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics

  2023cites this paper
• Type 1 Diabetes Mellitus: Inflammation, Mitophagy, and Mitochondrial Function.

  2023cites this paper
• Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons

  2022cites this paper
• CELEBRATING 100 YEARS OF INSULIN USE

  2022cites this paper
• Insulin-induced Lipo hypertrophy and factors affecting it in children and adolescents with type 1 diabetes mellitus: Review of Literature in the past 12 years

  2022cites this paper
• Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study

  2022cites this paper
• Generation of a Beta-Cell Transplant Animal Model of Diabetes Using CRISPR Technology.

  2022cites this paper
• Celebrating A Century Of Insulin Discovery: A Critical Appraisal Of The Emerging Alternative Insulin Delivery Systems.

  2022cites this paper
• Evaluation of Patient Reported Satisfaction and Clinical Efficacy of Insulin Glargine 300 U/mL Versus 100 U/mL in Patients With Type 1 Diabetes Using Flash Glucose Monitoring System

  2022cites this paper
• Diabetes in general

  2022cites this paper
• Pharmacological Management of Diabetes Mellitus: A Century of Expert Opinions in Cecil Textbook of Medicine

  2021cites this paper
• The Adaptation of the Carbohydrate Counting Method Affects HbA1c and Improves Anthropometric Indicators in Patients With Diabetes Mellitus 2

  2021cites this paper
• Insulin Availability and Affordability in the Urban Municipality of Antananarivo, Madagascar

  2021cites this paper
• Genome engineering and disease modeling via programmable nucleases for insulin gene therapy; promises of CRISPR/Cas9 technology

  2021cites this paper
• Extended Noninvasive Glucose Monitoring in the Interstitial Fluid Using an Epidermal Biosensing Patch.

  2021cites this paper
• Fish Protein and Its Derivatives: Functionality, Biotechnology and Health Effects

  2021cites this paper
• Fatty acids may influence insulin dynamics through modulation of albumin‐Zn2+ interactions

  2021cites this paper
• Profile Evaluation of Medication, Cost Comparison, and Clinical Outcome of Human and Analog Insulin Treatment to Type-2 Diabetes Mellitus Outpatient at Medistra Hospital Year 2012-2013

  2020cites this paper
• Recurrent Hypoglycemic Episodes with Hypoinsulinemia in a Patient with Diabetes.

  2020cites this paper
• Lentivirus mediated pancreatic beta-cell specific insulin gene therapy for STZ-induced Diabetes.

  2020cites this paper
• Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation

  2020cites this paper
• Comparison of four matrixes for diluting insulin in routine clinical measurements

  2020cites this paper
• Changes in the biochemical, hematological and histopathological parameters in STZ-Induced diabetic rats and the ameliorative effect of Kigelia africana fruit extract

  2020cites this paper
• Metabolism of bioconjugate therapeutics: why, when, and how?

  2020cites this paper
• Anti-diabetic Activity of Sanseviera liberica Gerome and Labroy (Agavaceae) Root Extract and Fractions on Alloxan-induced Diabetic Rats

  2019cites this paper
• COMPARISON OF INSULIN GLARGINE AND GLULISINE WITH INSULIN NPH AND REGULAR FOR GLYCEMIC CONTROL IN CHILDREN WITH TYPE –I DIABETES MELLITUS

  2019cites this paper
• Protective Effect of Human Mesenchymal Stem Cells on the Survival of Pancreatic Islets

  2019cites this paper
• Insulin: a review of analytical methods.

  2019cites this paper
• Initiation of Basal Insulin in Patients with Uncontrolled Type 2 Diabetes Mellitus

  2019cites this paper
• Analysis of Glulisine Crystallisation Utilising Phase Diagrams and Nucleants

  2019cites this paper
• Role of ultrafast-acting insulin analogues in the management of diabetes.

  2019cites this paper
• Serum Lactate Dehydrogenase Activity and Visceral Organs and Body Weights of Diabetic Rats Administered Single and Combinatorial Herbal Formulations

  2018cites this paper
• Investigation of insulin resistance in the popularly used four rat models of type-2 diabetes.

  2018cites this paper
• HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes

  2018cites this paper
• Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes

  2018cites this paper
• The effects of flow on therapeutic protein aggregation

  2018cites this paper
• Changes in hepato-renal tissues biomarkers of alloxan-induced diabetic Wistar rats co-administered monosodium glutamate and ascorbic acid

  2018cites this paper
• An Overview on the Insulin Preparations and Devices

  2018cites this paper
• C-peptides for diagnostics and therapy: a veterinary medicine point of view.

  2017cites this paper
• The impact of currently used oral antihyperglycemic drugs on dysfunctional adipose tissue

  2017cites this paper
• A comparative analysis of G-protein-coupled receptor and peptide ligand expression within human and mouse islets of Langerhans, and its application in exploring the role of CXCL14 in islet function

  2016influential citation
• Comparing Normal Insulin Physiology and Insulin Dysfunction in Diabetes Mellitus : Constructing Optimal Insulin-Based Regimens

  2016cites this paper
• Interactions of short-acting, intermediate-acting and pre-mixed human insulins with free radicals--Comparative EPR examination.

  2015cites this paper
• In vitro characteristics of an insulin suppository developed using palm oil base (HAMIN®) and its hypoglycaemic effect on rabbits

  2015cites this paper
• Relatório de estágio profissionalizante no Club de Golf de Miramar

  2015influential citation
• Incretins: Their physiology and application in the treatment of diabetes mellitus

  2014cites this paper
• GLP-1-mediated gene therapy approaches for diabetes treatment

  2014cites this paper